Tech Scouting Requirements

We are looking for oncology-focused antibody platforms and therapeutic assets in the following categories:

Technology Interests

1.       Novel Antibody Therapeutics

• Bi-specific, multi-specific, or first-in-class monoclonal antibodies targeting validated or novel cancer-related antigens.

Required Stage

• In vivo proof-of-concept (POC) data available.

2.       Antibody-Drug Conjugates (ADCs)

• Innovations in payload design, conjugation technology, or linker chemistry.

Required Stage:

• In vivo efficacy data required.

3.       Advanced Antibody Conjugate Platforms

• ARC (Antibody-Radionuclide Conjugates) for precise radiotherapeutic delivery.

• DAC (Degrader Antibody Conjugates) leveraging targeted protein degradation.

• PAC (PROTAC Antibody Conjugates) enabling degradation via antibody-guided PROTACs.

Required Stage:

• In vivo efficacy data required.

Problem Statement

Despite the advancement of antibody-based therapies, many oncology treatments still suffer from challenges in targeting specificity, resistance development, and systemic toxicity. There is a critical need for modular, next-generation antibody technologies that can overcome these limitations and offer durable, patient-centric solutions. Celltrion aims to bridge this gap by partnering with innovators who are developing scalable and clinically meaningful oncology therapeutics.

Why Apply?

This is a compelling opportunity to collaborate with Celltrion, a biopharmaceutical leader who developed the first biosimilar with deep expertise in drug development and biologics manufacturing. Celltrion is open to worldwide partnerships beyond the APAC region, offering selected innovators access to co-development, investment, licensing, and commercialization opportunities. Join us in shaping the next wave of antibody-based treatments that can transform lives and redefine care standards.

Submissions close on 30 June

Apply today to accelerate your antibody innovation and make a global impact in oncology care.

For inquiries, please contact startup.relations@ventureblick.com

创新具体要求

我们正在寻找以下类别的用于肿瘤治疗的抗体平台和候选药物：

技术方向

1. 新型抗体疗法

• 双特异性、多特异性或首创（first-in-class）的单克隆抗体，靶向已验证的或新型的癌症相关抗原。

阶段要求：

• 已有体内概念验证 (POC) 数据。

2. 抗体偶联药物 (ADC)

• 在有效载荷设计、偶联技术或化学连接子方面有所创新。

阶段要求：

需提供体内有效性数据。

3. 先进的抗体偶联平台

• ARC（抗体偶联核素药物），用于精确递送放射性核素。

• DAC（抗体偶联降解剂），通过降解靶蛋白进行治疗。

• PAC（PROTAC-抗体偶联物），通过抗体引导的 PROTAC 降解靶蛋白。

阶段要求：

• 需提供体内有效性数据。

当前挑战

尽管抗体疗法取得了进展，但许多肿瘤药物仍面临着靶向特异性、耐药性和毒副作用的挑战。我们亟需模块化的下一代抗体技术来克服这些局限性，提供持久的、以患者为中心的解决方案。Celltrion 致力于通过创新合作，让可规模扩展且具有临床意义的候选肿瘤疗法来弥补这些缺陷。

为何申请？

这是与领先的生物制药跨国公司 Celltrion 合作的一个绝佳机会。Celltrion 是世界上首个单克隆抗体生物类似药的开发者，拥有药物开发和生物制剂生产的卓越能力。Celltrion 积极在亚太地区乃至全球探索合作，将为其选择的创新伙伴提供共同开发、投资、许可和商业化的多种潜在机会。与我们携手，塑造下一代抗体药物疗法，刷新护理标准并点亮生命希望。

申请提交截止日：6 月 30 日

立即申请，加速您的抗体技术创新，扩大在肿瘤治疗领域的全球影响力。

如需咨询更多信息，请发送邮件至 startup.relations@ventureblick.com